Experimental Alzheimer’s drug hailed as breakthrough, side-effects in focus

The Daily Star – Reuters

An experimental Alzheimer’s disease drug from Eisai (4523.T) and Biogen (BIIB.O) slowed cognitive decline in a closely watched trial but may carry a risk of dangerous side effects for certain patients, according to new data presented on Tuesday. Read more on The Daily Star

Author: apdimcion

Leave a Reply

Your email address will not be published. Required fields are marked *